#news #biotech CRISPR/Cas9 Flexibility Slows Gene Editing Process

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: CRISPR/Cas9 Flexibility Slows Gene Editing Process .A team of Swedish molecular biologists has clarified the mechanism by which the CRISPR/Cas9 identifies and cleaves a specific DNA…

from Genomics/Proteomics | Bio Research International http://ift.tt/2zvPRC9

#news #biotech Johnson & Johnson drops sirukumab after FDA blow, cans phase 3 AML trial

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Johnson & Johnson drops sirukumab after FDA blow, cans phase 3 AML trial .Five months ago, Johnson & Johnson painted sirukumab and talacotuzumab as part of a wave of blockbusters-in-waiting that would drive growth for years to come. Today, J&J abandoned plans to win approval of its once-hyped rheumatoid arthritis drug sirukumab and stopped a phase 3 trial of talacotuzumab in acute myeloid leukemia (AML).

from FierceBiotech: Biotech http://ift.tt/2hKPYlp

#news #biotech Biotech builder Cydan gets cash injection for genetic disorders

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Biotech builder Cydan gets cash injection for genetic disorders .Drug accelerator Cydan has gained a $34 million injection as it eyes deeper inroads into rare diseases for its second fund. The company, which has spun out several biotechs, is looking to repeat its successes by using the cash boost to seek out preclinical rare disease candidates.

from FierceBiotech: Biotech http://ift.tt/2x26W5b

#news #biotech Matchmaking with consequences

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Matchmaking with consequences .Most human tumours have one thing in common: They harbour drastically increased amounts of the so-called Myc proteins. Animal experiments show that such high Myc concentrations contribute to causing cancer. But Myc proteins not only have harmful properties, they are also crucial in healthy cells: Acting as “transcription factors”, they control the activity of a limited number of genes. A lot of these genes activated by Myc are essential for the growth and proliferation of normal cells so that Myc is indispensable for normal human development.

from Biotechnology News – Biology News http://ift.tt/2yu7Vyb

#news #biotech AstraZeneca builds case for adding savolitinib to Iressa, Tagrisso

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: AstraZeneca builds case for adding savolitinib to Iressa, Tagrisso .AstraZeneca has posted preliminary phase 1b/2 data on the use of savolitinib in combination with Iressa or Tagrisso. Adding the MET tyrosine kinase inhibitor (TKI) to the approved drugs triggered partial responses in a significant minority of NSCLC patients who had progressed after treatment with an EGFR-TKI.

from FierceBiotech: Biotech http://ift.tt/2yp5DRK

#news #biotech Sanofi cancer executive jumps ship to Silicon Therapeutics

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Sanofi cancer executive jumps ship to Silicon Therapeutics .Sanofi veteran Christopher Winter has been appointed as the new chief of R&D at drug discovery biotech Silicon, becoming the latest in an increasingly long line of Big Pharma executives to join the early-stage life science stream.

from FierceBiotech: Biotech http://ift.tt/2yp5rSg

#news #biotech Tiny protein coiled coils that self-assemble into cages

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Tiny protein coiled coils that self-assemble into cages .(Phys.org)—A large team of researchers with members from Slovenia, the U.K, Serbia, France and Spain has developed a technique that causes proteins to self-assemble into geometric shapes on demand. In their paper published in the journal Nature Biotechnology, the group describes their technique and possible uses for the tiny cages.

from Biotechnology News – Biology News http://ift.tt/2gp0KB9

#news #biotech Need for speed makes genome editing efficient, if not better

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Need for speed makes genome editing efficient, if not better .Rice University researchers have developed a computational model to quantify the mechanism by which CRISPR-Cas9 proteins find their genome-editing targets.

from Biotechnology News – Biology News http://ift.tt/2x2Hrk2

#news #biotech Researchers find mechanism by which plant roots avoid oxygen-deficient soil

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Researchers find mechanism by which plant roots avoid oxygen-deficient soil .Researchers are warning about more frequently occurring extreme weather events in the future as a result of climate change. Current environmental catastrophes such as the numerous and particularly severe tropical hurricanes this year tend to confirm this trend. These extreme weather events are often accompanied by flooding, which increasingly affects agricultural land. This flooding is becoming an ever more serious problem for crop cultivation, because the majority of intensively grown crops are not very tolerant to too much water. Greater losses in yield are becoming apparent. At the same time, the pressure on the available agricultural land to produce crops is rapidly increasing in light of a growing global population.

from Biotechnology News – Biology News http://ift.tt/2xMoJSi

#news #biotech Gemini taps A-list VCs for $42M to fuel AMD R&D

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Gemini taps A-list VCs for $42M to fuel AMD R&D .Atlas Venture, Lightstone Ventures and OrbiMed have joined up to lead a $42.5 million investment in Gemini Therapeutics. The VCs put up the series A funds to equip Gemini to turn advances in our understanding of the genetics of age-related macular degeneration (AMD) into a drug pipeline.

from FierceBiotech: Biotech http://ift.tt/2xMOXnv